Document is current
Any future updates will be listed below
-
Authors
Leppek, Kathrin https://orcid.org/0000-0002-8012-8076
Byeon, Gun Woo
Kladwang, Wipapat
Wayment-Steele, Hannah K.
Kerr, Craig H.
Xu, Adele F. https://orcid.org/0000-0003-3332-5285
Kim, Do Soon
Topkar, Ved V.
Choe, Christian https://orcid.org/0000-0001-8871-9682
Rothschild, Daphna
Tiu, Gerald C.
Wellington-Oguri, Roger https://orcid.org/0000-0002-7818-2161
Fujii, Kotaro
Sharma, Eesha
Watkins, Andrew M.
Nicol, John J.
Romano, Jonathan https://orcid.org/0000-0003-4031-0102
Tunguz, Bojan
Diaz, Fernando
Cai, Hui
Guo, Pengbo https://orcid.org/0000-0002-2646-8133
Wu, Jiewei
Meng, Fanyu
Shi, Shuai
Participants, Eterna
Dormitzer, Philip R. https://orcid.org/0000-0003-0671-6360
Solórzano, Alicia https://orcid.org/0000-0003-0072-3463
Barna, Maria https://orcid.org/0000-0002-6843-4396
Das, Rhiju https://orcid.org/0000-0001-7497-0972
- License Information
-
More Information
Article History
Received: 8 April 2021
Accepted: 7 February 2022
First Online: 22 March 2022
Competing interests
: Stanford University has submitted provisional patent applications related to use of the <i>Hoxa9</i> P4 stem-loop (K.L. and M.B.), and the SARS-CoV2 5′ UTR (K.L. and M.B.), computational design of mRNAs (H.K.W.-S., D.S.K., C.C., E.S., R.D.), chemically modified nucleotides to stabilize RNA therapeutics (W.K. and R.D.), and design of reporter mRNAs and the PERSIST-seq platform (M.B., G.W.B., and K.L.). R.D., D.S.K., W.K., and C.H.K. have initiated a commercial venture focused on improving RNA design. R.D. received an honorarium for speaking at Pfizer′s 2021 mRNA science day. F.D., H.C., P.G., J.W., F.M., S.S., A.S., and P.R.D. are or were employees of Pfizer and may hold stock options. P.R.D. is currently an employee and shareholder of GlaxoSmithKline (GSK).
